 | • レポートコード：MRC2301A079 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、258ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医療 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の本調査レポートでは、2021年に9,614.20百万ドルであった世界の血中循環腫瘍細胞（CTC）市場規模が、2022年に10,932.26百万ドルに到達し、2027年まで年平均13.88%で成長して20,977.18百万ドルまで拡大すると予測しています。本レポートは、血中循環腫瘍細胞（CTC）の世界市場について総合的・多面的に調査・分析し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、検体別（血液、骨髄、その他体液）分析、技術別（CTC分析、CTC検出・濃縮方式、CTC直接検出方式）分析、製品別（採血管、器具、装置、キット・試薬）分析、用途別（臨床/リキッドバイオプシー、研究）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況、企業情報などを以下の構成でまとめております。本資料には、Advanced Cell Diagnostics, Inc.、ApoCell, Inc.、Aviva Biosciences、Bio-Techne Corporation、BioCep Ltd.、BIOCEPT, INC.、BioFluidica、Biolidics Limitedなどの企業情報が含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の血中循環腫瘍細胞（CTC）市場規模：検体別 - 血液における市場規模 - 骨髄における市場規模 - その他体液における市場規模 ・世界の血中循環腫瘍細胞（CTC）市場規模：技術別 - CTC分析における市場規模 - CTC検出・濃縮方式における市場規模 - CTC直接検出方式おける市場規模 ・世界の血中循環腫瘍細胞（CTC）市場規模：製品別 - 採血管における市場規模 - 器具・装置における市場規模 - キット・試薬における市場規模 ・世界の血中循環腫瘍細胞（CTC）市場規模：用途別 - 臨床/リキッドバイオプシーにおける市場規模 - 研究における市場規模 ・世界の血中循環腫瘍細胞（CTC）市場規模：地域別 - 南北アメリカの血中循環腫瘍細胞（CTC）市場規模 アメリカの血中循環腫瘍細胞（CTC）市場規模 カナダの血中循環腫瘍細胞（CTC）市場規模 ブラジルの血中循環腫瘍細胞（CTC）市場規模 … - アジア太平洋の血中循環腫瘍細胞（CTC）市場規模 中国の血中循環腫瘍細胞（CTC）市場規模 インドの血中循環腫瘍細胞（CTC）市場規模 韓国の血中循環腫瘍細胞（CTC）市場規模 台湾の血中循環腫瘍細胞（CTC）市場規模 … - ヨーロッパ/中東/アフリカの血中循環腫瘍細胞（CTC）市場規模 イギリスの血中循環腫瘍細胞（CTC）市場規模 ドイツの血中循環腫瘍細胞（CTC）市場規模 フランスの血中循環腫瘍細胞（CTC）市場規模 ロシアの血中循環腫瘍細胞（CTC）市場規模 … - その他地域の血中循環腫瘍細胞（CTC）市場規模 ・競争状況 ・企業情報 |
The Global Circulating Tumor Cell Market size was estimated at USD 9,614.20 million in 2021 and expected to reach USD 10,932.26 million in 2022, and is projected to grow at a CAGR 13.88% to reach USD 20,977.18 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Circulating Tumor Cell to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Specimen, the market was studied across Blood, Bone Marrow, and Other Body Fluids.
Based on Technology, the market was studied across CTC Analysis, CTC Detection & Enrichment Methods, and CTC Direct Detection Methods. The CTC Detection & Enrichment Methods is further studied across Combined Methods, Density-based Separation, Immunocapture, and Size-based Separation. The Immunocapture is further studied across Negative Selection and Positive Selection. The Size-based Separation is further studied across Membrane-based and Microfluidic-based.
Based on Product, the market was studied across Blood Collection Tubes, Devices or Systems, and Kits & Reagents.
Based on Application, the market was studied across Clinical/ Liquid Biopsy and Research. The Clinical/ Liquid Biopsy is further studied across Risk Assessment and Screening and Monitoring. The Research is further studied across Cancer Stem Cell & Tumorigenesis Research and Drug/Therapy Development.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Circulating Tumor Cell market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Circulating Tumor Cell Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Circulating Tumor Cell Market, including Advanced Cell Diagnostics, Inc., ApoCell, Inc., Aviva Biosciences, Bio-Techne Corporation, BioCep Ltd., BIOCEPT, INC., BioFluidica, Biolidics Limited, Canopus Bioscience Ltd., Creatv MicroTech, Inc., Epic Sciences, Fluxion Biosciences, Inc., Greiner Bio One International GmbH, Ikonisys Inc., IVDiagnostics, LungLife AI, Inc., Menarini Silicon Biosystems, Miltenyi Biotec, NanoString Technologies, Inc., Precision for Medicine, QIAGEN, Rarecells Diagnostics, ScreenCell, STEMCELL Technologies, Inc., Sysmex Corporation, and Vitatex, Inc.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Circulating Tumor Cell Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Circulating Tumor Cell Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Circulating Tumor Cell Market?
4. What is the competitive strategic window for opportunities in the Global Circulating Tumor Cell Market?
5. What are the technology trends and regulatory frameworks in the Global Circulating Tumor Cell Market?
6. What is the market share of the leading vendors in the Global Circulating Tumor Cell Market?
7. What modes and strategic moves are considered suitable for entering the Global Circulating Tumor Cell Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increased spending in cancer-related therapies
5.1.1.2. Growing prevalence of cancer across the globe
5.1.2. Restraints
5.1.2.1. Lack of awareness about CTC therapeutics
5.1.3. Opportunities
5.1.3.1. Technological advancements in bioengineering and biomedical practices
5.1.3.2. Demand for minimally invasive diagnostics in recent years
5.1.4. Challenges
5.1.4.1. Stringent government regulations for the approval of CTC technologies
5.2. Cumulative Impact of COVID-19
6. Circulating Tumor Cell Market, by Specimen
6.1. Introduction
6.2. Blood
6.3. Bone Marrow
6.4. Other Body Fluids
7. Circulating Tumor Cell Market, by Technology
7.1. Introduction
7.2. CTC Analysis
7.3. CTC Detection & Enrichment Methods
7.4.1. Combined Methods
7.4.2. Density-based Separation
7.4.3. Immunocapture
7.4.4.1. Negative Selection
7.4.4.2. Positive Selection
7.4.4. Size-based Separation
7.4.5.1. Membrane-based
7.4.5.2. Microfluidic-based
7.4. CTC Direct Detection Methods
8. Circulating Tumor Cell Market, by Product
8.1. Introduction
8.2. Blood Collection Tubes
8.3. Devices or Systems
8.4. Kits & Reagents
9. Circulating Tumor Cell Market, by Application
9.1. Introduction
9.2. Clinical/ Liquid Biopsy
9.3.1. Risk Assessment
9.3.2. Screening and Monitoring
9.3. Research
9.4.1. Cancer Stem Cell & Tumorigenesis Research
9.4.2. Drug/Therapy Development
10. Americas Circulating Tumor Cell Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Circulating Tumor Cell Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Circulating Tumor Cell Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.1.1. Quadrants
13.1.2. Business Strategy
13.1.3. Product Satisfaction
13.2. Market Ranking Analysis, By Key Player
13.3. Market Share Analysis, By Key Player
13.4. Competitive Scenario
13.4.1. Merger & Acquisition
13.4.2. Agreement, Collaboration, & Partnership
13.4.3. New Product Launch & Enhancement
13.4.4. Investment & Funding
13.4.5. Award, Recognition, & Expansion
14. Company Usability Profiles
14.1. Advanced Cell Diagnostics, Inc.
14.1.1. Business Overview
14.1.2. Key Executives
14.1.3. Product & Services
14.2. ApoCell, Inc.
14.2.1. Business Overview
14.2.2. Key Executives
14.2.3. Product & Services
14.3. Aviva Biosciences
14.3.1. Business Overview
14.3.2. Key Executives
14.3.3. Product & Services
14.4. Bio-Techne Corporation
14.4.1. Business Overview
14.4.2. Key Executives
14.4.3. Product & Services
14.5. BioCep Ltd.
14.5.1. Business Overview
14.5.2. Key Executives
14.5.3. Product & Services
14.6. BIOCEPT, INC.
14.6.1. Business Overview
14.6.2. Key Executives
14.6.3. Product & Services
14.7. BioFluidica
14.7.1. Business Overview
14.7.2. Key Executives
14.7.3. Product & Services
14.8. Biolidics Limited
14.8.1. Business Overview
14.8.2. Key Executives
14.8.3. Product & Services
14.9. Canopus Bioscience Ltd.
14.9.1. Business Overview
14.9.2. Key Executives
14.9.3. Product & Services
14.10. Creatv MicroTech, Inc.
14.10.1. Business Overview
14.10.2. Key Executives
14.10.3. Product & Services
14.11. Epic Sciences
14.11.1. Business Overview
14.11.2. Key Executives
14.11.3. Product & Services
14.12. Fluxion Biosciences, Inc.
14.12.1. Business Overview
14.12.2. Key Executives
14.12.3. Product & Services
14.13. Greiner Bio One International GmbH
14.13.1. Business Overview
14.13.2. Key Executives
14.13.3. Product & Services
14.14. Ikonisys Inc.
14.14.1. Business Overview
14.14.2. Key Executives
14.14.3. Product & Services
14.15. IVDiagnostics
14.15.1. Business Overview
14.15.2. Key Executives
14.15.3. Product & Services
14.16. LungLife AI, Inc.
14.16.1. Business Overview
14.16.2. Key Executives
14.16.3. Product & Services
14.17. Menarini Silicon Biosystems
14.17.1. Business Overview
14.17.2. Key Executives
14.17.3. Product & Services
14.18. Miltenyi Biotec
14.18.1. Business Overview
14.18.2. Key Executives
14.18.3. Product & Services
14.19. NanoString Technologies, Inc.
14.19.1. Business Overview
14.19.2. Key Executives
14.19.3. Product & Services
14.20. Precision for Medicine
14.20.1. Business Overview
14.20.2. Key Executives
14.20.3. Product & Services
14.21. QIAGEN
14.21.1. Business Overview
14.21.2. Key Executives
14.21.3. Product & Services
14.22. Rarecells Diagnostics
14.22.1. Business Overview
14.22.2. Key Executives
14.22.3. Product & Services
14.23. ScreenCell
14.23.1. Business Overview
14.23.2. Key Executives
14.23.3. Product & Services
14.24. STEMCELL Technologies, Inc.
14.24.1. Business Overview
14.24.2. Key Executives
14.24.3. Product & Services
14.25. Sysmex Corporation
14.25.1. Business Overview
14.25.2. Key Executives
14.25.3. Product & Services
14.26. Vitatex, Inc
14.26.1. Business Overview
14.26.2. Key Executives
14.26.3. Product & Services
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing